Abstract:AMV@NanoCip, a novel biomimetic nanomedicine, integrates PBP2a antibody‐presenting nanovesicles with self‐assembled ciprofloxacin nanoparticles exhibiting sonodynamic properties. This formulation demonstrates exceptional MRSA‐targeting and antibacterial efficacy, achieving 99.99% sterilization in vitro and significant bacterial reduction in a pneumonia model. The sequential treatment strategy, combining adhesion, membrane disruption, and synergistic therapy, presents a promising approach for combating bacterial infections. Bacterial‐induced lower respiratory tract infections are a growing global health concern, exacerbated by the inefficacy of conventional antibiotics and delivery methods to effectively target the lower respiratory tract, leading to suboptimal therapeutic outcomes. To address this challenge, this work engineers PBP2a antibody‐presenting membrane nanovesicles (AMVs) specifically designed to target the penicillin‐binding protein variant on the surface of methicillin‐resistant Staphylococcus aureus (MRSA). Concurrently, this work develops pure ciprofloxacin nanoparticles (NanoCip) that, for the first time, exhibits exceptional self‐generated sonodynamic properties, attributed to hydrogen‐bond‐driven self‐assembly, while maintaining their inherent pharmacological efficacy. These NanoCip particles are integrated with AMVs to create a novel biomimetic nanomedicine, AMV@NanoCip. This formulation demonstrated remarkable MRSA‐targeting affinity in both in vitro and in vivo models, significantly enhancing antibacterial activity. Upon ultrasound stimulation, AMV@NanoCip achieves over 99.99% sterilization of MRSA in vitro, with a reduction exceeding 5.14 Log CFU. Prokaryotic transcriptomic analysis further elucidates the synergistic mechanisms by which AMV@NanoCip, coupled with ultrasound, disrupts the MRSA exoskeleton. In a MRSA‐induced pneumonia animal model, AMV@NanoCip+US results in a substantial bacterial load reduction in the lungs (99.99%, 4.02 Log CFU). This sequential treatment strategy (adhesion‐membrane disruption‐synergistic therapy) offers significant promise as an innovative therapeutic approach for combating bacterial infections.

Magnetically-targetable outer-membrane vesicles for sonodynamic eradication of antibiotic-tolerant bacteria in bacterial meningitis

Sonoactivated Chemodynamic Therapy: A Robust ROS Generation Nanotheranostic Eradicates Multidrug‐Resistant Bacterial Infection

Sono-Immunotherapeutic Nanocapturer to Combat Multidrug-Resistant Bacterial Infections

Precise magnetic resonance imaging-guided sonodynamic therapy for drug-resistant bacterial deep infection

Bacteria-Responsive Nanoliposomes as Smart Sonotheranostics for Multidrug Resistant Bacterial Infections

Inflammation‐Activated Endogenous Macrophage‐Mediated Prodrug Delivery System Overcoming Biological Barriers for Enhanced Oral Meningitis Therapy

IR780 Based Sonotherapeutic Nanoparticles to Combat Multidrug-Resistant Bacterial Infections

Multi-Modal Imaging Monitored M2 Macrophage Targeting Sono-Responsive Nanoparticles to Combat MRSA Deep Infections

A magnetic-guided nano-antibacterial platform for alternating magnetic field controlled vancomycin release in staphylococcus aureus biofilm eradication

Sono‐Triggered Biomimetically Nanoantibiotics Mediate Precise Sequential Therapy of MRSA‐Induced Lung Infection

Treatment of MRSA-infected osteomyelitis using bacterial capturing, magnetically targeted composites with microwave-assisted bacterial killing

Red Blood Cell Membrane-Camouflaged Vancomycin and Chlorogenic Acid-Loaded Gelatin Nanoparticles Against Multi-Drug Resistance Infection Mice Model

Precise Clearance of Intracellular MRSA via Internally and Externally Mediated Bioorthogonal Activation of Micro/Nano Hydrogel Microspheres

Infection microenvironment-triggered nanoparticles eradicate MRSA by thermally amplified chemodynamic therapy and M1 macrophage

Magnetically Guided Nanoworms for Precise Delivery to Enhance in Situ Production of Nitric Oxide to Combat Focal Bacterial Infection in Vivo.

Versatile Chlorin E6-Based Magnetic Polydopamine Nanoparticles for Effectively Capturing and Killing MRSA

A Smart Nanovector of Cationic Starch Modified Curcumin with Excellent Targeting and Sonodynamic Properties for Effective Therapy of MRSA‐Induced Osteomyelitis

Dual-targeting tigecycline nanoparticles for treating intracranial infections caused by multidrug-resistant Acinetobacter baumannii

Mrna-Laden Lipid-Nanoparticle-Enabled in Situ CAR-Macrophage Engineering for the Eradication of Multidrug-Resistant Bacteria in a Sepsis Mouse Model.

A Smart Bacteria‐Capture‐Killing Vector for Effectively Treating Osteomyelitis Through Synergy Under Microwave Therapy

Magnetron Traps Therapeutics for Localized Bacterial Capture and Overcome Ulcer Infection